ARCH Venture Partners XII, LLC bought PRME
February 15, 2024 · Form 4 insider transaction
ARCH Venture Partners XII, LLC bought 3,200,000 shares of Prime Medicine, Inc. at $6.25 per share, a transaction worth $20.00M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 5 days after the transaction.
Footnotes
Represents shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the general partner of AVP XII LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.